SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Landec Corp/CA – ‘8-K’ for 10/11/12

On:  Tuesday, 10/16/12, at 12:27pm ET   ·   For:  10/11/12   ·   Accession #:  1437749-12-10333   ·   File #:  0-27446

Previous ‘8-K’:  ‘8-K’ on 9/27/12 for 9/26/12   ·   Next:  ‘8-K’ on 11/14/12 for 11/13/12   ·   Latest:  ‘8-K’ on 4/30/24 for 4/29/24   ·   18 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/16/12  Landec Corp/CA                    8-K:5,9    10/11/12    2:208K                                   RDG Filings/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 2: EX-3.1      Articles of Incorporation/Organization or By-Laws   HTML    107K 


8-K   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2012

LANDEC CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)
     
(Commission file number)
 
94-3025618
(IRS Employer Identification No.)
     
3603 Haven Avenue, Menlo Park, California 94025
(Address of principal executive offices and zip code)

(650) 306-1650
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 5.03                       Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Effective as of October 11, 2012, the stockholders of Landec Corporation (the “Company”) approved an amendment to its Bylaws to increase the number of authorized directors to no fewer than six (6) and no more than ten (10).  Attached as Exhibit 3.1 to this filing is a copy of the Amended and Restated Bylaws, as amended through October 11, 2012.

Item 5.07                      Submission of Matters to a Vote of Security Holders.

           On October 11, 2012, the Company held its Annual Meeting of Stockholders.  The four proposals presented to stockholders were the amendment to the Bylaws to increase the number of authorized directors to no fewer than six (6) and no more than ten (10), the election of four Class 1 directors, the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending May 26, 2013, and a non-binding advisory proposal approving executive compensation.

 
1.
The amendment to the Bylaws was approved, with votes as follows: 20,255,040 votes for approval and 97,031 votes against approval, with 81,026 votes abstaining and 3,575,932 broker non-votes.

 
2.
The voting results for the election of directors were as follows:

Director
Votes For
Votes Withheld
Broker Non Votes
Gary T. Steele
20,006,095 427,002 3,575,932
Frederick Frank
19,995,971 437,126 3,575,932
Steven Goldby
20,111,551 321,546 3,575,932
Stephen E. Halprin
20,004,789 428,308 3,575,932

All of the nominees were elected to serve two year terms.

3.           Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending May 26, 2013, with votes as follows: 23,933,604 votes for approval and 67,572 votes against approval, with 7,853 votes abstaining.

4.           Stockholders approved the compensation paid to the Company’s named executive officers (in the form of a non-binding, advisory vote), with votes as follows:

For
Against
Abstain
Broker Non-Votes
20,101,583 210,387 121,127 3,575,932

Item 9.01                      Financial Statements and Exhibits.
 
Exhibit No.
 
Description
   
         
3.1
 
Amended and Restated Bylaws of the Company
   
 
 
 

 
SIGNATURE
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
             
   
LANDEC CORPORATION
Registrant
   
             
 
By:
     
           
       
Vice President of Finance and
   
       
Chief Financial Officer
   
 
 
 
 
 

 

EXHIBIT INDEX
 
Exhibit No.
 
Description
   
         
3.1
 
Amended and Restated Bylaws of the Company
   
 
 
 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
5/26/1310-K
Filed on:10/16/12
For Period End:10/11/12DEF 14A,  PRE 14A
 List all Filings 


18 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/20/24  Lifecore Biomedical, Inc./DE      10-K        5/28/23  138:75M
 6/06/23  Lifecore Biomedical, Inc./DE      S-1/A                  2:365K                                   Workiva Inc Wde… FA01/FA
 6/02/23  Lifecore Biomedical, Inc./DE      10-Q        2/26/23   63:8.3M
 4/06/23  Lifecore Biomedical, Inc./DE      S-1                    4:527K                                   Workiva Inc Wde… FA01/FA
 4/06/23  Lifecore Biomedical, Inc./DE      S-8         4/06/23    4:97K
 3/16/23  Lifecore Biomedical, Inc./DE      10-Q       11/27/22   62:6.8M
 3/16/23  Lifecore Biomedical, Inc./DE      10-Q/A      8/28/22   69:7.6M
 3/16/23  Lifecore Biomedical, Inc./DE      10-K/A      5/29/22  129:20M
10/07/22  Lifecore Biomedical, Inc./DE      10-Q        8/28/22   60:5.8M
 9/14/22  Lifecore Biomedical, Inc./DE      10-K        5/29/22  112:17M
 4/07/22  Lifecore Biomedical, Inc./DE      10-Q        2/27/22   64:8.1M
 1/07/22  Lifecore Biomedical, Inc./DE      10-Q       11/28/21   61:6.9M
10/05/21  Lifecore Biomedical, Inc./DE      10-Q        8/29/21   60:5.8M
 7/29/21  Lifecore Biomedical, Inc./DE      10-K        5/30/21  107:13M
 4/08/21  Lifecore Biomedical, Inc./DE      10-Q        2/28/21   70:7.4M
 1/07/21  Lifecore Biomedical, Inc./DE      10-Q       11/29/20   72:7.4M
10/07/20  Lifecore Biomedical, Inc./DE      10-Q        8/30/20   72:7.1M
 8/14/20  Lifecore Biomedical, Inc./DE      10-K        5/31/20  107:16M
Top
Filing Submission 0001437749-12-010333   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 6:56:44.2pm ET